ABL Bio Inc.

KOSDAQ 298380.KQ

ABL Bio Inc. Free Cash Flow for the year ending December 31, 2023: USD -26.27 M

ABL Bio Inc. Free Cash Flow is USD -26.27 M for the year ending December 31, 2023, a -148.55% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

ABL Bio Inc. Free Cash Flow for the year ending December 31, 2022 was USD 54.11 M, a 254.40% change year over year.
ABL Bio Inc. Free Cash Flow for the year ending December 31, 2021 was USD -35.05 M, a 20.34% change year over year.
ABL Bio Inc. Free Cash Flow for the year ending December 31, 2020 was USD -44.00 M, a -84.30% change year over year.
ABL Bio Inc. Free Cash Flow for the year ending December 31, 2019 was USD -23.87 M, a -90.93% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

KOSDAQ: 298380.KQ

ABL Bio Inc.

CEO	Dr. Sang Hoon Lee Ph.D.
IPO Date	Dec. 19, 2018
Location	South Korea
Headquarters	16 Daewangpangyo-Ro 712 Beon-Gil
Employees	102
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. The company is headquartered in Seongnam, South Korea.

Key trends

Past 5 years